NASDAQ:REGN
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.'s revenue grew 1.0% in fiscal 2025 to $14.3B while operating margin fell to 24.9%, its lowest in 10 years. Free cash flow was $4.1B, 28.4% of revenue, and the diluted share count fell 5.6%.Summary generated from Regeneron Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 4, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$14.3B
Revenue growth+1.0%
Revenue, 5-yr CAGR+11.0%
Gross marginn/a
Operating margin24.9%
Net margin31.4%
ROIC10.5%
Return on equity14.9%
Debt / equity0.06
Free cash flow$4.1B
FCF margin28.4%
Share count change−5.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 16.1 | 12.2 | 13.1 | 14.2 | 14.3 |
| Operating income | 8.9 | 4.7 | 4.0 | 4.0 | 3.6 |
| Net income | 8.1 | 4.3 | 4.0 | 4.4 | 4.5 |
| Free cash flow | 6.5 | 4.4 | 3.9 | 3.7 | 4.1 |
Recent filings
- 8-KEntry into a material agreement
Oct 6, 2026 - 8-KDirector or officer change
Sep 30, 2026 - 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 6, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026